formaldehyde has been researched along with Prostatic Hyperplasia in 11 studies
paraform: polymerized formaldehyde; RN given refers to parent cpd; used in root canal therapy
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In addition, 101 PCa patient samples, 13 benign prostatic hyperplasia (BPH) and 12 normal adjacent tissue samples, were assayed by PS and SS to evaluate their detection abilities for K-Ras mutations in codons 12 and 13." | 1.38 | Application of pyrosequencing technique for improved detection of K-Ras mutation in formalin-fixed and paraffin-embedded prostate carcinoma tissues in Chinese patients. ( Bo, J; Huang, Y; Li, D; Liang, G; Liu, D; Liu, W; Pan, J; Ping, P; Sha, J; Shen, W; Xuan, H, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (27.27) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 4 (36.36) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nikitina, AS | 1 |
| Sharova, EI | 1 |
| Danilenko, SA | 1 |
| Butusova, TB | 1 |
| Vasiliev, AO | 1 |
| Govorov, AV | 1 |
| Prilepskaya, EA | 1 |
| Pushkar, DY | 1 |
| Kostryukova, ES | 1 |
| Ni, J | 1 |
| Mizoguchi, S | 1 |
| Bernardi, K | 1 |
| Suzuki, T | 1 |
| Kurobe, M | 1 |
| Takaoka, E | 1 |
| Wang, Z | 1 |
| DeFranco, DB | 1 |
| Tyagi, P | 1 |
| Gu, B | 1 |
| Yoshimura, N | 1 |
| Stewart, GD | 1 |
| Baird, J | 1 |
| Rae, F | 1 |
| Nanda, J | 1 |
| Riddick, AC | 1 |
| Harrison, DJ | 1 |
| Sha, J | 1 |
| Liang, G | 1 |
| Pan, J | 1 |
| Xuan, H | 1 |
| Ping, P | 1 |
| Li, D | 1 |
| Bo, J | 1 |
| Liu, D | 1 |
| Shen, W | 1 |
| Liu, W | 1 |
| Huang, Y | 1 |
| Bibikova, M | 1 |
| Yeakley, JM | 1 |
| Chudin, E | 1 |
| Chen, J | 1 |
| Wickham, E | 1 |
| Wang-Rodriguez, J | 1 |
| Fan, JB | 1 |
| Miyoshi, Y | 1 |
| Uemura, H | 1 |
| Ishiguro, H | 1 |
| Kitamura, H | 1 |
| Nomura, N | 1 |
| Danenberg, PV | 1 |
| Kubota, Y | 1 |
| Hood, BL | 1 |
| Darfler, MM | 1 |
| Guiel, TG | 1 |
| Furusato, B | 1 |
| Lucas, DA | 1 |
| Ringeisen, BR | 1 |
| Sesterhenn, IA | 1 |
| Conrads, TP | 1 |
| Veenstra, TD | 1 |
| Krizman, DB | 1 |
| Buchanan, LJ | 1 |
| Riches, AC | 1 |
| Alkhouja, AS | 1 |
| Gazaigne, J | 1 |
| Abel, PD | 1 |
| Keane, P | 1 |
| Leathem, A | 1 |
| Tebbutt, S | 1 |
| Williams, G | 1 |
| Koda, A | 1 |
| Hiramatsu, M | 1 |
| Yoshida, Y | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase II Trial of Pemetrexed and Bevacizumab for Recurrent Ovarian and Primary Peritoneal Carcinoma[NCT00868192] | Phase 2 | 38 participants (Actual) | Interventional | 2008-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Overall response rate = complete response + partial response~Complete response = disappearance of all target and non-target lesions and no evidence of new lesions documented by two disease assessments at least 4 weeks apart.~Partial response = at least a 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD. There can be non unequivocal progression of non-target lesions and no new lesions." (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 41 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: 12 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 79 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) |
|---|---|
| Pemetrexed and Bevacizumab | 25.7 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) |
|---|---|
| Pemetrexed and Bevacizumab | 56 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) |
|---|---|
| Pemetrexed and Bevacizumab | 7.9 |
A CA-125 response was defined as at least a 50% reduction in CA-125 levels from a pretreatment sample following guidelines described by the Gynecological Cancer Intergroup. (NCT00868192)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| 50% CA-125 response | 75% CA-125 response | No CA-125 response | |
| Pemetrexed and Bevacizumab | 17 | 8 | 2 |
OS = observed length of time from entry into the study to death or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) | ||
|---|---|---|---|
| Platinum-free interval of <6 months | Platinum-free interval of 6-12 months | Platinum-free interval of >12 months | |
| Pemetrexed and Bevacizumab | 16.7 | 24.9 | 28.0 |
PFS = Period from study entry until disease progression, death, or date of last contact (NCT00868192)
Timeframe: Median follow-up was 25.7 months (range 3.0-47.2 months)
| Intervention | months (Median) | ||
|---|---|---|---|
| Platinum-free interval of <6 months | Platinum-free interval of 6-12 months | Platinum-free interval of >12 months | |
| Pemetrexed and Bevacizumab | 6.7 | 4.7 | 16.8 |
As measured by RECIST criteria (NCT00868192)
Timeframe: 6 months
| Intervention | participants (Number) | |||
|---|---|---|---|---|
| Complete response | Partial response | Stable disease | Progressive disease | |
| Pemetrexed and Bevacizumab | 0 | 14 | 18 | 2 |
Detailed serious adverse events and other adverse events are shown in the adverse event module of the results. (NCT00868192)
Timeframe: 6 months
| Intervention | percentage of participants (Number) | ||||
|---|---|---|---|---|---|
| Grade 3/4 hematologic toxicity | Most common non-hematologic toxicity - fatigue | Grade 3 renal toxicity | Gastrointestinal toxicity | Subsequently developed hematologic malignancies | |
| Pemetrexed and Bevacizumab | 53 | 94 | 6 | 91 | 6 |
11 other studies available for formaldehyde and Prostatic Hyperplasia
| Article | Year |
|---|---|
Novel RNA biomarkers of prostate cancer revealed by RNA-seq analysis of formalin-fixed samples obtained from Russian patients.
Topics: Aged; Formaldehyde; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Gene Regulato | 2017 |
Long-lasting bladder overactivity and bladder afferent hyperexcitability in rats with chemically-induced prostatic inflammation.
Topics: Animals; Disease Models, Animal; Formaldehyde; Male; Neurons, Afferent; Patch-Clamp Techniques; Pros | 2019 |
Utilizing mRNA extracted from small, archival formalin-fixed paraffin-embedded prostate samples for translational research: assessment of the effect of increasing sample age and storage temperature.
Topics: Analysis of Variance; Biopsy; Formaldehyde; Humans; Male; Paraffin Embedding; Prostate; Prostatic Hy | 2011 |
Application of pyrosequencing technique for improved detection of K-Ras mutation in formalin-fixed and paraffin-embedded prostate carcinoma tissues in Chinese patients.
Topics: Aged; Asian People; Carcinoma; Case-Control Studies; Cell Line, Tumor; Codon; Fixatives; Formaldehyd | 2012 |
Gene expression profiles in formalin-fixed, paraffin-embedded tissues obtained with a novel assay for microarray analysis.
Topics: Adenocarcinoma; Breast Neoplasms; Colonic Neoplasms; Female; Fixatives; Formaldehyde; Gene Expressio | 2004 |
Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer.
Topics: Cell Differentiation; Dihydrouracil Dehydrogenase (NADP); DNA Primers; Formaldehyde; Gene Expression | 2005 |
Proteomic analysis of formalin-fixed prostate cancer tissue.
Topics: Amino Acid Sequence; Cytokines; Formaldehyde; Gene Expression Profiling; Gene Expression Regulation, | 2005 |
A histochemical comparison of acid phosphatase activity in human BPH and rat ventral prostate.
Topics: Acid Phosphatase; Animals; Epithelium; Formaldehyde; Histocytochemistry; Humans; Male; Prostate; Pro | 1984 |
[Reduction of the weight of prostatic tissue during transurethral resection].
Topics: Acetic Acid; Fixatives; Formaldehyde; Humans; Male; Organ Size; Picrates; Prostate; Prostatectomy; P | 1997 |
Change in glycoconjugate for the binding site of the lectin Ulex europeus 1 following malignant transformation of prostatic epithelium.
Topics: Aged; Aged, 80 and over; Binding Sites; Cell Transformation, Neoplastic; Formaldehyde; Frozen Sectio | 1989 |
[Pharmacological study of prostate extracts. (IV). Prostatic acid phosphotases from several different species, and the effect of prostate extracts on these enzymes].
Topics: Acid Phosphatase; Adrenal Glands; Animals; Cysteine; Drug Combinations; Ethamsylate; Ethanol; Formal | 1974 |